Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 240 versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 240 versus SCANLUX 300.
OMNIPAQUE 240 vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays due to high atomic number of iodine, enhancing vascular and tissue contrast during imaging procedures. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
Intravenous administration: 50-200 mL (12-48 g iodine) of OMNIPAQUE 240 (240 mg iodine/mL) as a single dose, adjusted for procedure and patient size.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Primarily renal (glomerular filtration, no tubular reabsorption); >95% excreted unchanged in urine within 24 hours; <5% biliary/fecal
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent